A randomized, double-blind, placebo-controlled, multicenter trial assessing the reduction of the rate of lipoprotein apheresis after treatment with pelacarsen (TQJ230) compared to placebo in patients with hyperlipoproteinemia(a) and established cardiovascular disease undergoing weekly lipoprotein apheresis in Germany - Trial 2021-003059-41
Access comprehensive clinical trial information for 2021-003059-41 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma AG and is currently Ongoing. The study focuses on Cardiovascular Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2021-003059-41
Ongoing
Trial Details
EU Clinical Trials Register • 2021-003059-41
A randomized, double-blind, placebo-controlled, multicenter trial assessing the reduction of the rate of lipoprotein apheresis after treatment with pelacarsen (TQJ230) compared to placebo in patients with hyperlipoproteinemia(a) and established cardiovascular disease undergoing weekly lipoprotein apheresis in Germany
Study Focus
Sponsor & Location
Novartis Pharma AG
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Cardiovascular disease, unspecified
Hypertensive heart disease
Heart disease, unspecified
Atherosclerotic cardiovascular disease, so described
Atherosclerotic heart disease
Data Source
EU Clinical Trials Register
2021-003059-41
Non-Device Trial